All the Active Ingredient Drugs
Interleukin Inhibitor. Ixekizumab 80 mg/ml. PRE FILL. PEN: 1.
160 mg by SC inject. (Two 80 mg inject.) at Week 0, follow. by 80 mg (1 injec.) at Weeks 2, 4, 6, 8, 10, and 12, then maint. dosing of 80 mg (1 inj.) every 4 wks. Consider. should be given to discount. tmt. in pts. who have shown no response after 16 -20 wks. of tmt. Some pts. with init. partial response may subseq. improve with contin. tmt. beyond 20 wks.
Psoriatic arthritis:
alone or in comb. with methotrexate, for the tmt of active psoriatic arthritis in adults who have responded inadeq. to, or who are intol. to one or more dis.-modifying anti-rheumatic drug (DMARD) ther.
Ankylosing spondylitis (radiographic axial spondyloarthritis):
for the tmt of adults with active ankylosing spondylitis who have responded inadeq. to conventional ther.
Non-radiographic axial spondyloarthritis:
tmt of adults with active non-radiographic axial spondyloarthritis with objective signs of inflamm. as indicated by elevated C-reactive protein (CRP) and MRI who have responded inadeq. to nonsteroidal anti-inflammatory drugs (NSAIDs).
C/I: Serious hypersens. Clinical. important active infec.
